Bibliographic Details
| Title: |
Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers? |
| Authors: |
Messner DA; Donna A. Messner, PhD, Center for Medical Technology Policy, 401 E. Pratt Street, Suite 631, Baltimore, MD 21202, Tel: 410.547.2686 x101, Fax: 410.547.5088, Email: donna.messner@cmtpnet.org., Rabins P, Downing AC, Irizarry M, Foster NL, Al Naber J, Dabbous O, Fillit H, Gabler S, Krakauer R, Lotz D, Payzant E, Schneider L, Tyrone J, Van Amerongen D, Wuest D |
| Source: |
The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2019; Vol. 6 (1), pp. 20-26. |
| Publication Type: |
Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: |
Publisher: Elsevier Country of Publication: United States NLM ID: 101638820 Publication Model: Print Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE |
| Database: |
MEDLINE Ultimate |
